You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SBRT, low dose radiotherapy, PARP inhibitor, PD-1,PD-L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy Trial in Chengdu (Low Dose Radiotherapy, stereotactic body

Not yet recruiting
  • NSCLC
  • +3 more
  • Low Dose Radiotherapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 11, 2022

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

Recruiting
  • Colorectal Liver Metastases
  • Radiation: High- and Low-dose radiotherapy
  • PD-1 Inhibitors
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Sep 13, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Acute Myeloid Leukemia Trial (Azacitidine, Donor lymphocyte infusion, Camrelizumab)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Mar 15, 2023

Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

Terminated
  • Ovarian Neoplasms
  • +3 more
  • AK112 low dose
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Oct 8, 2022

Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Beijing, China
  • +1 more
Sep 21, 2023

NSCLC Trial in Wuhan (Camrelizumab, Apatinib, Docetaxel injection)

Recruiting
  • Non-Small Cell Lung Cancer
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 29, 2022

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

Breast Cancer Trial in Tucson (Rucaparib)

Active, not recruiting
  • Breast Cancer
  • Tucson, Arizona
    University of Arizona Cancer Center
Feb 24, 2022

Nasopharyngeal Carcinoma, De-escalation Therapy Trial in Guangzhou (Cisplatin-based induction chemo, Full course of PD-1/PD-L1

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escalation Therapy
  • Cisplatin-based induction chemotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 16, 2023

Radiotherapy, PD-1 Inhibitor, Capecitabine Trial in Zhuhai (SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1

Recruiting
  • Radiotherapy
  • +3 more
  • SBRT radiotherapy + Conventionally fractionated radiotherapy
  • +2 more
  • Zhuhai, Guangdong, China
    Fifth Affilliated Hospital of Sun Yat-sen University
Apr 13, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab, gemcitabin, cisplatin
  • Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jun 19, 2022

Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Intensity-modulated radiotherapy (IMRT)
  • +3 more
  • Wuhan, Hubei, China
    Renmin hosptial of Wuhan University
Jun 16, 2023

Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Sacramento (Anti-PD-L1 Monoclonal Antibody MPDL3280A,

Terminated
  • Recurrent Non-Small Cell Lung Carcinoma
  • Stage IV Non-Small Cell Lung Cancer
  • Anti-PD-L1 Monoclonal Antibody MPDL3280A
  • Stereotactic Body Radiation Therapy
  • Sacramento, California
    University of California Davis
Aug 2, 2022

Solid Tumor Trial in Richmond (Stereotactic radiotherapy, Biological: humanized anti-PD-1 mAb, Biological: humanized anti-PD-L1

Completed
Has Results
  • Solid Tumor
  • Stereotactic radiotherapy
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 20, 2021

Chronic Hepatitis b Trial in Auckland (AB-101, Placebo, Nucleos(t)ide Analogue)

Not yet recruiting
  • Chronic Hepatitis b
  • Auckland, New Zealand
    New Zealand Clinical Research Auckland
Jul 26, 2023

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

Metastatic NSCLC (NSCLC) Trial in Sacramento (Avelumab, Stereotactic ablative radiotherapy (SAR))

Completed
  • Metastatic Non-small Cell Lung Cancer (NSCLC)
  • Avelumab
  • Stereotactic ablative radiotherapy (SAR)
  • Sacramento, California
    UC Davis
Oct 19, 2021

Carcinoma, Solid Tumor Trial in China (ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
  • Changchun, China
  • +18 more
Nov 4, 2021

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022